The cardiovascular safety of diabetes drugs - Insights from the rosiglitazone experience

HiattW.R.; KaulS.; SmithR.J.

首页> 外文期刊>The New England journal of medicine >The cardiovascular safety of diabetes drugs - Insights from the rosiglitazone experience

【24h】

The cardiovascular safety of diabetes drugs - Insights from the rosiglitazone experience

机译：糖尿病药物的心血管安全性-罗格列酮经验的启示

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The management of type 2 diabetes has been challenged by uncertainty about possible cardiovascular effects related to treatment intensity and choice of drug. Although the Food and Drug

机译：2型糖尿病的治疗受到与治疗强度和药物选择有关的可能的心血管作用的不确定性的挑战。虽然食品和药品

著录项

来源
《The New England journal of medicine》 |2013年第14期|共3页
作者
HiattW.R.; KaulS.; SmithR.J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. The cardiovascular safety of diabetes drugs - Insights from the rosiglitazone experience [J] . HiattW.R., KaulS., SmithR.J. The New England journal of medicine . 2013,第14期

机译：糖尿病药物的心血管安全 - 来自罗格列酮经验的见解
2. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials [J] . P. D. Home, S. E. Kahn, N. P. Jones, Diabetologia . 2010,第9期

机译：在随机对照的ADOPT（一项糖尿病结果进展试验）和RECORD（罗格列酮评估糖尿病的心血管结果和糖血症的调节性）临床试验中，口服降糖药发生恶性肿瘤的经验
3. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials [J] . P. D. Home, S. E. Kahn, N. P. Jones, Diabetologia: clinical and experimental diabetes and metabolism . 2010,第9期

机译：在随机对照的ADOPT（一项糖尿病结果进展试验）和RECORD（罗格列酮评估糖尿病的心血管结果和血糖调节）临床试验中口服降糖药的恶性肿瘤经验
4. Novel Insight into the Underlying Pathophysiology of Diabetes-induced Cardiovascular Dysfunction Using the Berg Interrogative Biology~(TM) Discovery Platform [C] . Min Du, Tracey Friss, Rangaprasad Sarangarajan, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：使用BERG疑问生物学〜（TM）发现平台对糖尿病诱导的心血管功能障碍潜在病理生理学的新颖洞察力
5. Ambient PM Exposure and RAGE: Insight into an Emerging Risk for Diabetes and Cardiovascular Disease. [D] . Vaughan, Joshua M. 2015

机译：大气PM暴露和愤怒：洞悉糖尿病和心血管疾病的新兴风险。
6. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials [O] . P. D. Home, S. E. Kahn, N. P. Jones, -1

机译：在随机对照的ADOPT（糖尿病结果进展试验）和RECORD（罗格列酮评估糖尿病的心血管结果和血糖调节）临床试验中口服降糖药引起的恶性肿瘤的经验
7. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials [O] . P. D. Home, null null, S. E. Kahn, 2010

机译：在随机对照的ADOPT（糖尿病结果进展试验）和RECORD（罗格列酮评估糖尿病的心血管结果和血糖调节）临床试验中口服降糖药引起的恶性肿瘤的经验

The cardiovascular safety of diabetes drugs - Insights from the rosiglitazone experience

摘要

著录项

相似文献

相关主题

期刊订阅